BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

961 related articles for article (PubMed ID: 17576169)

  • 1. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
    Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
    J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis.
    Ishii M; Iwai K; Koike M; Ohshima S; Kudo-Tanaka E; Ishii T; Mima T; Katada Y; Miyatake K; Uchiyama Y; Saeki Y
    J Bone Miner Res; 2006 Jun; 21(6):965-76. PubMed ID: 16753027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR1 acts downstream of NFAT2 in osteoclastogenesis and enhances cell migration.
    Ishida N; Hayashi K; Hattori A; Yogo K; Kimura T; Takeya T
    J Bone Miner Res; 2006 Jan; 21(1):48-57. PubMed ID: 16355273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.
    Balkan W; Martinez AF; Fernandez I; Rodriguez MA; Pang M; Troen BR
    Gene; 2009 Oct; 446(2):90-8. PubMed ID: 19563866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANKL-induced schlafen2 is a positive regulator of osteoclastogenesis.
    Lee NK; Choi HK; Yoo HJ; Shin J; Lee SY
    Cell Signal; 2008 Dec; 20(12):2302-8. PubMed ID: 18796328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular acidification enhances osteoclast survival through an NFAT-independent, protein kinase C-dependent pathway.
    Pereverzev A; Komarova SV; Korcok J; Armstrong S; Tremblay GB; Dixon SJ; Sims SM
    Bone; 2008 Jan; 42(1):150-61. PubMed ID: 17964236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
    Merle B; Itzstein C; Delmas PD; Chenu C
    J Cell Biochem; 2003 Oct; 90(2):424-36. PubMed ID: 14505357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms.
    Yagi M; Ninomiya K; Fujita N; Suzuki T; Iwasaki R; Morita K; Hosogane N; Matsuo K; Toyama Y; Suda T; Miyamoto T
    J Bone Miner Res; 2007 Jul; 22(7):992-1001. PubMed ID: 17402846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.
    Egusa H; Doi M; Saeki M; Fukuyasu S; Akashi Y; Yokota Y; Yatani H; Kamisaki Y
    Bone; 2011 Aug; 49(2):264-74. PubMed ID: 21504804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
    Tsuji-Naito K
    Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.